Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy

被引：0
|
作者：
Marcia Waddington-Cruz
Leslie Amass
Denis Keohane
Jeffrey Schwartz
Balarama Gundapaneni
Hui Hua Li
机构：
[1] Neuromuscular Diseases Unit,Hospital Universitario Clementino
[2] Pfizer,undefined
[3] Pfizer,undefined
[4] Pfizer,undefined
[5] Pfizer,undefined
[6] Pfizer,undefined
[7] Pfizer,undefined
[8] InVentiv Health,undefined
来源：
Orphanet Journal of Rare Diseases | / 10卷 / Suppl 1期
关键词：
Registration Trial; Open Label Extension; Additional Categorization; Continue Evaluation; Treatment Start;
D O I：
10.1186/1750-1172-10-S1-P12
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Evaluation of one year treatment with tafamidis in Portuguese patients with transthyretin familial amyloid polyneuropathy
    Coelho, T.
    Conceicao, I.
    Cardoso, M.
    Monteiro, C.
    Alves, C.
    Rodrigues, C.
    Pereira, P.
    Silva, A. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 327 - 327
  • [22] Evaluation of one year treatment with tafamidis in Portuguese patients with transthyretin familial amyloid polyneuropathy
    Coelho, T.
    Conceicao, I.
    Cardoso, M.
    Monteiro, C.
    Alves, C.
    Rodrigues, C.
    Pereira, P.
    Silva, A. M.
    JOURNAL OF NEUROLOGY, 2014, 261 : S221 - S221
  • [23] Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
    Suhr O.B.
    Conceição I.M.
    Karayal O.N.
    Mandel F.S.
    Huertas P.E.
    Ericzon B.-G.
    Neurology and Therapy, 2014, 3 (2) : 101 - 112
  • [24] Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years
    Barroso, Fabio A.
    Judge, Daniel P.
    Ebede, Ben
    Li, Huihua
    Stewart, Michelle
    Amass, Leslie
    Sultan, Marla B.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 (03): : 194 - 204
  • [25] Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
    Keohane, D.
    Schwartz, J.
    Gundapaneni, B.
    Stewart, M.
    Amass, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 413 - 413
  • [26] Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy
    McKeage K.
    Lyseng-Williamson K.A.
    Scott L.J.
    Drugs & Therapy Perspectives, 2017, 33 (2) : 47 - 53
  • [27] Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
    Denis Keohane
    Jeffrey Schwartz
    Balarama Gundapaneni
    Michelle Stewart
    Leslie Amass
    Orphanet Journal of Rare Diseases, 10 (Suppl 1)
  • [28] A Comprehensive Evaluation of the Disease-Modifying Effects of Tafamidis in Patients with Transthyretin Type Familial Amyloid Polyneuropathy
    Coelho, Teresa
    Maia, Luis
    da Silva, Ana Martins
    Cruz, Marcia Waddington
    Plante-Bordeneuve, Violaine
    Lozeron, Pierre
    Suhr, Ole B.
    Campistol, Josep
    Conceicao, Isabel
    Schmidt, Hartmut
    Trigo, Pedro
    Packman, Jeff
    Grogan, Donna R.
    NEUROLOGY, 2011, 76 (09) : A111 - A111
  • [29] Early diagnosis in patients with transthyretin familial amyloid polyneuropathy: A comparative study
    Raya-Cruz, Manuel
    Buades-Reines, Juan
    Gallego-Lezaun, Cristina
    Ripoll-Vera, Tomas
    Uson-Martin, Mercedes
    Cisneros-Barroso, Eugenia
    MEDICINA CLINICA, 2017, 148 (02): : 63 - 66
  • [30] Erratum to: Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy
    Kate McKeage
    Katherine A. Lyseng-Williamson
    Lesley J. Scott
    Drugs & Therapy Perspectives, 2017, 33 (2) : 54 - 55
12345